Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NMBR | P28336 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567830 | 0.87 | CYP2C19 (0.41) | SIRT2CYP2C19HIF1ANMBR | |
| SCHEMBL14458143 | 0.78 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL312947 | 0.75 | SIRT2 (0.39) | SIRT2CYP2C19HIF1AKDM4EALDH1A1 | |
| SCHEMBL313247 | 0.74 | CYP17A1 (0.42) | SIRT2 | |
| SCHEMBL13053078 | 0.73 | CYP11B1 (0.42) | SIRT2CYP2C19 | |
| SCHEMBL17859348 | 0.70 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL7368138 | 0.70 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL25453639 | 0.69 | SIRT2 (0.55) | SIRT2CYP2C19NMBR | |
| SCHEMBL5688831 | 0.68 | SIRT2 (0.42) | SIRT2CYP2C19ALDH1A1 | |
| SCHEMBL31285310 | 0.68 | L3MBTL1 (0.37) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629472-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20070276143-A1 | Method for producing optically active compound | YAMANO TORU | 2007-11-29 | — | — | US | disclosed |
| EP-1489070-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7247732-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060229457-A1 | Method for producing optically active compound | YAMANO TORU | 2006-10-12 | — | — | US | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276143-A1 | Method for producing optically active compound | CYP8B1, HRH3, HRH1 | SIRT2 1128/4885CYP2C19 79/4885HIF1A 399/4885 |
| US-20060229457-A1 | Method for producing optically active compound | CYP8B1, HSD11B1, HSD17B7 | SIRT2 1117/4885CYP2C19 107/4885HIF1A 421/4885 |
| US-20050107433-A1 | Process for production of optically active compounds | CYP8B1, HSD11B1, CYP51A1 | SIRT2 1689/4885CYP2C19 60/4885HIF1A 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.